Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | XPO1 | O14980 | 3/20 | 0.38 |
| ▸ | NCF1 | P14598 | 1/20 | 0.38 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | CRHR1 | P34998 | 4/20 | 0.34 |
| ▸ | APAF1 | O14727 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.33 |
| ▸ | ACP1 | P24666 | 1/20 | 0.33 |
| ▸ | SMPD3 | Q9NY59 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22489583 | 0.76 | CYP1A2 (0.45) | CYP1A2CYP3A4TDP1ALOX15TSHR | |
| SCHEMBL20880323 | 0.76 | XPO1 (0.54) | CYP1A2CYP3A4TDP1ALOX15TSHR | |
| SCHEMBL13865687 | 0.74 | RAB9A (0.39) | CYP1A2TSHRHSD17B10GAAL3MBTL1 | |
| SCHEMBL14108957 | 0.73 | CYP2C19 (0.40) | TSHRAR | |
| SCHEMBL21139679 | 0.72 | KDM4E (0.42) | CYP1A2TDP1GAAL3MBTL1 | |
| SCHEMBL12093307 | 0.72 | NCF1 (0.42) | CYP1A2CYP3A4TDP1ALOX15TSHR | |
| SCHEMBL22193255 | 0.72 | NCF1 (0.38) | CYP1A2CYP3A4TDP1ALOX15TSHR | |
| SCHEMBL12093314 | 0.72 | NOS3 (0.46) | CYP1A2CYP3A4TSHRHSD17B10NCF1 | |
| SCHEMBL16256879 | 0.71 | CYP11B1 (0.37) | XPO1AR | |
| SCHEMBL18639310 | 0.71 | KMT2A (0.34) | CYP1A2CYP3A4TDP1ALOX15TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11505541-B2 | Protein kinase C inhibitors and methods of their use | NOVARTIS AG (CH) | 2022-11-22 | — | — | US | disclosed |
| US-20210387962-A1 | PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2021-12-16 | — | — | US | disclosed |
| US-11059804-B2 | Protein kinase C inhibitors and methods of their use | NOVARTIS AG (CH) | 2021-07-13 | — | — | US | disclosed |
| EP-3177608-B1 | PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2019-09-18 | — | — | EP | disclosed |
| EP-3514151-A1 | PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE | Novartis AG (CH) | 2019-07-24 | — | — | EP | disclosed |
| US-20190202809-A1 | PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2019-07-04 | — | — | US | disclosed |
| US-20180179181-A1 | PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2018-06-28 | — | — | US | disclosed |
| US-9845309-B2 | Protein kinase C inhibitors and methods of their use | NOVARTIS AG (CH) | 2017-12-19 | — | — | US | disclosed |
| US-9845309-B2 | Protein kinase C inhibitors and methods of their use | NOVARTIS AG (CH) | 2017-12-19 | — | — | US | disclosed |
| US-20160347737-A1 | PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2016-12-01 | — | — | US | disclosed |
| US-20160347737-A1 | PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2016-12-01 | — | — | US | disclosed |
| US-9452998-B2 | Protein kinase C inhibitors and methods of their use | NOVARTIS AG (CH) | 2016-09-27 | — | — | US | disclosed |
| US-20160046605-A1 | PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2016-02-18 | — | — | US | disclosed |
| WO-2016020864-A1 | PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2016-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210387962-A1 | PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE | PRKCA, PRKCB, PRKCH | CYP1A2 2906/4885CYP3A4 1675/4885TDP1 1077/4885 |
| US-11505541-B2 | Protein kinase C inhibitors and methods of their use | PRKCA, PRKCB, PRKCH | CYP1A2 2906/4885CYP3A4 1675/4885TDP1 1077/4885 |
| US-20160046605-A1 | PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE | PRKCA, PRKCB, PRKCH | CYP1A2 2906/4885CYP3A4 1675/4885TDP1 1077/4885 |
| US-11059804-B2 | Protein kinase C inhibitors and methods of their use | PRKCA, PRKCB, PRKCH | CYP1A2 2906/4885CYP3A4 1675/4885TDP1 1077/4885 |
| US-20160347737-A1 | PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE | PRKCA, PRKCB, PRKCH | CYP1A2 2906/4885CYP3A4 1675/4885TDP1 1077/4885 |
| US-20180179181-A1 | PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE | PRKCA, PRKCB, PRKCH | CYP1A2 2906/4885CYP3A4 1675/4885TDP1 1077/4885 |
| US-20190202809-A1 | PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE | PRKCA, PRKCB, PRKCH | CYP1A2 2906/4885CYP3A4 1675/4885TDP1 1077/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.